

# Universal Treatment for CRS

## Primary Focus: Oncology

### ABOUT CYTOAGENTS

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CTO1681 is positioned to become a new best practice in medicine.


### BENEFITS OF CTO1681

- Complete NDA Safety Package
- Phase 1 Human Clinical Trial Complete
- Immune Modulator Data in 25+ Cytokines
- Steroid Sparing Solution
- Reduction in Lung Weights: Key Metric in Translating to Human Efficacy
- Awarded \$3.6M NIH Non-Dilutive Grants
- US Manufacturing Partnership Established
- New Chemical Entity to US and Europe
- Multi Layered Patent Filings Covered Up to 2041

## Problem

IMMUNE SYSTEM OVERREACTS CAUSING EXCESSIVE INFLAMMATION, LEADING TO SEVERE ILLNESS AND MORTALITY

ONCE IN MOTION, “CYTOKINE STORM” CAN BE MORE DAMAGING THAN ITS TRIGGERING CONDITION(S)



## Solution

CTO1681 INHIBITS NF-KB ACTION THROUGH PROSTANOID RECEPTORS, REDUCING INFLAMMATION, & CALMING CYTOKINE RELEASE SYNDROME: SAFE & EFFECTIVE TREATMENT


*“Cellular therapy is a rapidly growing field that doesn’t show any likelihood of slowing.”*

—Dr. Matthew Frigault

## Approach

FAST TRACK TO HUMAN EFFICACY DATA  
ACCESS BILLION DOLLAR MARKETS

CTO1681: PURSUE BREAKTHROUGH STATUS ACQUISITION/LICENSING TARGET 2024



## PREVENTION AND TREATMENT OF CRS TRIGGERED BY CAR T-CELL AND BISPECIFIC ANTIBODY THERAPY

### MANAGEMENT

**Teresa Whalen, RPh, CEO**  
*Siemens Medical Systems  
University of Pittsburgh*

**Jodi Craigo, PhD, CSO**  
*University of Pittsburgh*

**Todd Lorenz, MD, CMO**  
*Portola Pharmaceuticals  
Stanford University*

**James Nolan,  
Business Development**  
*Wyeth, Institutes for  
Pharmaceutical Discovery*

**Roy Prieb, MBA, CFO**  
*Kleo Pharmaceuticals  
Boston Consulting Group*

**Denise Gottfried, MBA,  
Regulatory**  
*TekTeam*

**Ray Miller, JD, IP Attorney**  
*TroutmanPepper*

### ADVISORS

**Stanley M. Marks, MD**  
*UPMC Hillman Cancer Center*

**Angela Shen, MD, MBA**  
*Mass General Brigham  
Gene & Cell Therapy*

**Matthew Frigault, MD**  
*Mass General Hospital  
Cancer Center*

**John Friedman, JD**  
*Easton Capital Group*

**Roger Green**  
*Commercialization  
Strategy Expert*

**Boyle Chang, PhD  
Neuroscience**  
*Neuroscience Institute, AHN  
Carnegie Mellon University*

**Cheryl Armstrong, MD**  
*Denver University Health*

## CytoAgents Team